Uni-Bio Science Group Limited

690 KYG9198H1406

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 01:06:47 2024-04-29 am EDT			5-day change	1st Jan Change
0.085 ^HKD	0.00%		+2.41%	+18.06%

Mar. 27	Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 14	Uni-Bio Science's Profit to Climb in 2023	MT

Uni-Bio Science Group Limited Provides Financial Guidance for the Year Ended 31 December 2022

March 06, 2023 at 03:33 am EST

Uni-Bio Science Group Limited provided financial guidance for the year ended 31 December 2022. The Group is expected to record a profit attributable to the owners of the parent of not less than HKD 36 million (2021: loss of HKD 19.6 million) for the Year.

Latest news about Uni-Bio Science Group Limited

Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Uni-Bio Science's Profit to Climb in 2023	Feb. 14	MT
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023	Feb. 13	CI
Chinese Regulator NMPA Accepts Uni-Bio's Marketing Application for Eye Drops	Jan. 23	MT
Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration	Jan. 23	CI
China Grants Uni-Bio Science's Injection for Orthopedic Diseases	Jan. 22	MT
Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration	Jan. 21	CI
Uni-Bio Science Group Limited commences an Equity Buyback for 636,476,815 shares, representing 10% of its issued share capital, under the authorization approved on May 19, 2023.	Dec. 13	CI
Uni-Bio Science Group Limited Announces the Resignation of Ms. Zhang Yanfen as Executive Director	Nov. 15	CI
Uni-Bio Science's Unit Grants 7.2 Million Yuan Loan to Taili Biomedical Technology	23-09-18	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director	23-08-11	CI
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Uni-Bio Science Group Limited Provides Financial Guidance for the Year Ended 31 December 2022	23-03-06	CI
Uni-Bio Science Unit Renews Property Lease for Two Years	22-12-23	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration	22-06-28	CI
Uni-Bio Science CFO Resigns	22-04-01	MT
Uni-Bio Science Group Limited Announces Resignation of She Shi Bin Richard as Chief Financial Officer	22-03-31	CI
Uni-Bio Science Group Limited Announces Executive Changes	22-03-31	CI
Uni-Bio Science Narrows Loss on Higher Core Drugs Sales in 2021; Shares Rise 3%	22-03-22	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Uni-Bio Science Arm Signs R&D Deal for Medical Aesthetics Materials Development	22-01-05	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021	21-08-11	CI

Chart Uni-Bio Science Group Limited

Duration

Period

More charts

Company Profile

Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
UNI-BIO SCIENCE GROUP LIMITED	+18.06%	66.92M
CSL LIMITED	-4.02%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals